5 hours ago
1
Jonathan Ponciano, The Motley Fool
Sun, January 11, 2026 astatine 10:59 AM CST 5 min read
-
The main aesculapian serviceman of AnaptysBio sold 3,650 shares for $163,191.50 connected Thursday.
-
The transaction represented 8.0% of Paul Lizzul's nonstop communal banal holdings, reducing his nonstop involvement from 45,738 to 42,088 shares, arsenic reported.
-
No indirect holdings were involved; the disposition was wholly nonstop and resulted from an enactment workout with contiguous merchantability of a information of underlying shares.
-
These 10 stocks could mint the adjacent question of millionaires ›
Paul F. Lizzul, the main aesculapian serviceman of AnaptysBio (NASDAQ:ANAB), reported the nonstop merchantability of 3,650 shares of the institution for a full information of astir $163,191.50 connected Thursday, arsenic disclosed successful a caller SEC Form 4 filing.
| Shares sold (direct) | 3,650 |
| Transaction value | $163,191.50 |
| Post-transaction shares (direct) | 42,088 |
| Post-transaction worth (direct ownership) | $1.84 million |
Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($44.71); post-transaction worth calculated utilizing Thursday holdings and the trade-date adjacent price.
-
What is the circumstantial derivative discourse for this transaction?
The transaction progressive the workout of 8,525 options with 3,650 shares instantly sold, portion the remainder accrued the insider's nonstop stock count. -
How does the size of this commercialized comparison to anterior administrative events?
The 3,650 shares sold exceeds the caller administrative median of 2,227.5 shares. -
Did this filing impact indirect ownership oregon related entities?
No, each shares progressive were held straight by Paul F. Lizzul, with nary indirect positions oregon spot holdings reported post-transaction.
| Price (as of Thursday) | $44.71 |
| Market capitalization | $1.24 billion |
| Revenue (TTM) | $169.47 million |
| 1-year terms change | 214.36% |
-
AnaptysBio develops antibody-based therapeutics targeting inflammation and immuno-oncology, with cardinal programs including imsidolimab, rosnilimab, and ANB032.
-
The institution generates gross done clinical-stage merchandise development, milestone payments, and licensing agreements with large pharmaceutical partners.
-
It collaborates with large pharmaceutical partners focused connected dermatological and immune-mediated diseases.
AnaptysBio is simply a clinical-stage biotechnology institution specializing successful the improvement of caller antibody therapeutics for inflammatory and immunological conditions. The institution leverages strategical collaborations and licensing agreements to beforehand its pipeline and monetize its intelligence property. With a focused portfolio and partnerships with manufacture leaders, AnaptysBio aims to code important unmet aesculapian needs successful immunology and inflammation.
English (CA) · 
English (US) · 
Spanish (MX) ·